Oncotelic Therapeutics (OTLC) Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
OTLC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Oncotelic Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.08 |
| 52 Week High | US$0.11 |
| 52 Week Low | US$0.024 |
| Beta | -0.76 |
| 1 Month Change | -18.16% |
| 3 Month Change | 11.29% |
| 1 Year Change | 119.67% |
| 3 Year Change | 77.69% |
| 5 Year Change | -62.81% |
| Change since IPO | -27.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| OTLC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -14.9% | 1.1% | 1.2% |
| 1Y | 119.7% | 26.3% | 15.8% |
Return vs Industry: OTLC exceeded the US Biotechs industry which returned 27.1% over the past year.
Return vs Market: OTLC exceeded the US Market which returned 15.8% over the past year.
Price Volatility
| OTLC volatility | |
|---|---|
| OTLC Average Weekly Movement | 17.0% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: OTLC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: OTLC's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 26 | Vuong Trieu | www.oncotelic.com |
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications. It develops antisense and small molecule injectable drugs for the treatment of cancer. The company is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Oncotelic Therapeutics, Inc. Fundamentals Summary
| OTLC fundamental statistics | |
|---|---|
| Market cap | US$38.40m |
| Earnings (TTM) | -US$1.67m |
| Revenue (TTM) | n/a |
Is OTLC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OTLC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.67m |
| Earnings | -US$1.67m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0038 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 171.7% |
How did OTLC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/26 15:38 |
| End of Day Share Price | 2025/12/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oncotelic Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Theodore O'Neill | Litchfield Hills Research, LLC |